Table 4.
Adverse events after ingestion of CVD 103-HgR live oral cholera vaccine or placebo (adapted from [22]).
| no. of cases with symptoms after administration |
|||||||
|---|---|---|---|---|---|---|---|
| during first 4 days of follow-up |
during entire 12 days of follow-up |
||||||
| HIV status | treatment | diarrhoea | fever | emesis | diarrhoea | fever | emesis |
| seronegative | vaccine | 1/31 (3) | 4/37 (11) | 0/38 (0) | 1/27 (4) | 5/34 (15) | 1/34 (3) |
| placebo | 1/31 (3) | 3/37 (8) | 0/38 (0) | 2/27 (7) | 6/34 (18) | 1/34 (3) | |
| seropositive | vaccine | 2/30 (7) | 4/37 (11) | 0/27 (0) | 2/27 (7) | 6/36 (17) | 1/34 (3) |
| placebo | 1/30 (3) | 6/37 (16) | 1/27 (3) | 1/27 (4) | 6/36 (17) | 1/34 (3) | |